Abstract 2340P
Background
Tim3 (T-cell immunoglobulin and mucin-domain containing molecule3) plays an important role in metastatic spread of cancers. The blood brain barrier (BBB) is an essential barrier that breast cancer cells have to overcome to metastasize to the CNS. This study investigated the association/functionality of Tim3 in breast cancer cells and in the invasiveness of cerebral endothelial cells by cancer cells.
Methods
Human cerebral microvessel endothelial cells (hCMEC/D3) were used to model BBB in vitro. Tim3 knockdown was by anti-Tim3 siRNA in MCF-7 and MDA-MB-231 cell lines. Electric cell impedance sensing (ECIS) was used for assessing cellular attachment and migration. Transepithelial resistance (TEER) and paracellular permeability (PCP) were used to test the barrier functions of the cells. Cellular response to docetaxel was evaluated and shown as IC50.The effects of Tim3 knockdown on penetration through the hCMEC/D3 monolayer were also assessed.
Results
Tim3 knockdown (Tim3kd) cell models were successfully established with MCF-7 and MDA-MB-231 cells. Loss of Tim3 in these cells resulted in a decrease in both cell adhesiveness and migration. The knockdown also led to a reduced transepithelial resistance as shown by TEER assay and an increase in paracellular permeability when compared with wild type (WT) cells. It was noted that loss of Tim3 rendered both MCF-7 and MDA-MB-231 cells resistant to docetaxel (IC50 for WT and Tim3kd respectively being 0.86nM vs 2.2nM for MCF7 and 1.35nM vs 11.8nM for MDA-MB-231). In the cerebral endothelial cell invasion assay, we found that Tim3 knockdown in both MCF-7 and MDA-MB-231 resulted in a significantly reduced invasion of the breast cancer cells through the endothelium (31±8 vs 24±8 for MCF7, p=0.018; 211±48 vs 142±54 for MDA-MB-231, p<0.001, WT and Tim3kd respectively).
Conclusions
Tim3 has a marked influence on the barrier functions, adhesiveness and the sensitivity to docetaxel of breast cancer cells. Loss of Tim3 in breast cancer cells reduces tumour cell's penetration of cerebral endothelium. Collectively, Tim3 plays a key role in the maintenance of barrier functions in breast cancer and their potential breach of the blood brain barrier.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2222P - Frequent TERT gains in metastatic papillary thyroid carcinoma
Presenter: Sara Gil
Session: Poster session 16
2223P - Next-generation sequencing enables identification of RET rearrangements in papillary thyroid cancer
Presenter: Sergi Clavé
Session: Poster session 16
2224P - Identifying prognostic factors in patients with radioiodine-refractory differentiated thyroid carcinoma (RR-DTC) treated with tyrosine kinase inhibitors (TKI): Data from REGETNE registry
Presenter: Maria Victoria San Roman Gil
Session: Poster session 16
2225P - FOX1 (rs965513), NKX2-1 (rs944289) and BRAF (V600E) gene mutations and their role in development of papillary thyroid cancer
Presenter: Darko Katalinic
Session: Poster session 16
2226P - Survival benefit of radioiodine therapy (RAI) in papillary thyroid cancer variants (PTCV): A SEER analysis
Presenter: Sakhr Alshwayyat
Session: Poster session 16
2227P - The efficacy and safety of lenvatinib in neoadjuvant therapy in patients with locally advanced thyroid cancer: A single-arm phase II clinical trial
Presenter: Jianhong Yu
Session: Poster session 16
2228P - Long-term clinical outcomes of Lenvatinib in patients with differentiated thyroid cancer: Results from the real-world practice of a single institution
Presenter: Ryutaro Onaga
Session: Poster session 16
2229P - Updated safety and efficacy of selpercatinib in patients (pts) with RET-activated thyroid cancer: Data from LIBRETTO-001
Presenter: Lori Wirth
Session: Poster session 16
2323P - Multi-omic spatial phenotyping of the NSCLC tumour microenvironment for the development of a spatial score associated with immunotherapy resistance
Presenter: Arutha Kulasinghe
Session: Poster session 16
2324P - Trametinib and PD-1 combined blockade impairs tumor growth and improves survival of KRAS-mutant lung cancer through Id1 downregulation
Presenter: Ander Puyalto
Session: Poster session 16